HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado...
-
Upload
arleen-beasley -
Category
Documents
-
view
212 -
download
0
Transcript of HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado...
![Page 1: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/1.jpg)
HOT TOPICS IN BREAST CANCER11 NOVEMBRE 2009
CHIETI
Mediterranean School of Oncology
Prof Corrado Ficorella
Università degli Studi dell’Aquila
![Page 2: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/2.jpg)
Anthracyclines in Early Breast Cancer: Is It the End of an Era?
In light of emerging clinical data on :taxanes and biologic agents
In light of emerging preclinical/clinical data on :tumor biomarkers (HER2, TOP2A)
“Oxford Overview”
15.000 women, 17 trialsAnthracyclines-based regimens > Non-anthracyclines-based regimens
Absolute 3% to 4.5% improvement in RFS and OS
EBCTCG Lancet 2005
![Page 3: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/3.jpg)
Anthracyclines vs Taxanes: few trials
Study HR PUSON 9735: 4 AC v 4 DC (1016 pts) 0.6 .015
CALGB 9344: 4 AC v 4 AC→P (3121) 0.83 .006
NSABP B-28: 4 AC v 4 AC→4 P (3060)0.83 .006
MD Anderson: 8 FAC v 4 P→4 FAC (524) 0.66 .09
ECTO: 4 A→4 CMF v 4 AP→4 CMF (904) 0.66 .01
BCIRG 001: 6 FAC v 6 DAC (1491) 0.72 .001
PACS 01: 6 FEC v 3 FEC→3 D (1999) 0.83 .04
NCIC CTG MA21: 4 AC→4 P(arm A) v
6 CEF (arm B) v dd 6 EC→4 P (arm C) 1.49 (A v B) .005
1.68 (A v C) .0006
0.89 (C v B) .46
GEICAM 9906: 4 FEC→8 wP v 6 FEC 0.74 .006
![Page 4: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/4.jpg)
4 x DC(75/600) is associated with an OS benefit vs 4 x AC(60/600): 7-years Follow-Up of USON Trial 9735
(S Jones JCO 2009)
1016 pts, stage I to III, N+/-, HR +/-/unknown, CT-naive 170 pts assessed for HER2ResultsDFS 81% TC vs 75% AC HR, 0.74 P=.033OS 87% TC vs 82% AC HR, 0.69 P=.032
TC > AC in older as well as younger pts, tolerable regimenNo interaction of HR status or HER2 status and treatment
Older women more febrile neutropenia (TC): 8% vs 4% ,1 toxic death
more anemia (AC): G3/4 5% vs < 1%Three late deaths without relapse in AC group:
CHF,myelodysplasia,myelofibrosis
![Page 5: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/5.jpg)
4 x DC(75/600) is associated with an OS benefit vs 4 x AC(60/600): 7-years Follow-Up of US Oncology
Research Trial 9735 (S Jones JCO 2009)
Implication TC effective in various subsets, anthracyclines might not benefit HER2-disease, anthracyclines may be obsolete in early BC.The investigators propose TC for N0,lower risk N+, HER2- Breast Canc
Limitations N+ pts (?) : AC is not right comparator/most efficacious regimen
AC→P is the standard in N+ ptsEfficacy in HER2+/- pts; HR+/- pts; in older and younger pts (?):
unplanned exploratory analysessmall sample size
The trial did not included a combined anthracycline-taxane regimen(HER2- pts → 6x DC vs 6x DAC)My opinion: TC as another option (cardiotoxicity concerns), not as a
justification for eliminating other options.
![Page 6: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/6.jpg)
HER2 Status and Efficacy of Adjuvant Anthracyclines in early BC: A Pooled Analysis of Randomized Trials
A Gennari JNCI 2008
Pooled subset analysis within randomized clinical trials (anthracyclinesvs non anthracyclines-based regimens and efficacy data according toHER2 status)Eight studies (1536/5354 pts HER2+ BC)
Anthracyclines regimens (vs non Anthracyclines) HER2+ disease: DFS pooled HR, 0.71 P< .001
OS pooled HR, 0.73 P< .001HER2- disease: DFS pooled HR, 1 P = .75
OS pooled HR,1.03 P = .6Conclusions
The added benefits of adjuvant CT with anthracyclines appear to beconfined to women who have HER2 overexpressed/amplified BC
![Page 7: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/7.jpg)
HER2 Status and Efficacy of Adjuvant Anthracyclines in early BC: A Pooled Analysis of Randomized Trials
A Gennari JNCI 2008
Limitations
Reliance on published data;
Heterogeneity in the methods and definitions of HER2 positivity;
Lack of an indipendent/centralized assessment of HER2 status;
More than 50% of pts from NSABP B11 and B15 trials ( examination of
predictive role of HER2 was unplanned and retrospective in both);
B15 trial evaluated after the positive findings in the B11 trial
![Page 8: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/8.jpg)
Anthracyclines and HER2 Status
NSABP B23 (B. Fisher JCO 2001)
Pts HER2+ appeared to benefit more from CMF than from AC
(HR, 1.27; P= .46)
BR9601 trial (J.M.S. Bartlett JCO 2008)
Pts with normal HER1, HER2 (FISH), or HER3 levels
showed significantly increased
RFS ( HR, 0.36; P= .035) and OS ( HR, 0.30; P= .023)
when treated with epi-CMF vs CMF
![Page 9: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/9.jpg)
HER2 Status and different dose intensities of adjuvant anthracyclines
Studies have shown that the benefits of more intensive anthracyclines
based regimens were limited to pts HER2+
Muss HB NEJM 1994; Di Leo Clin Canc Res 2002; Del Mastro Br J Cancer 05
Another study shoved no association between HER2+ tumors and
incremental benefit for doses of doxorubicin > 60mg/mq
Hayes DF NEJM 2007
A metanalysis of studies of HER2 status and higher-dose vs standard
dose of anthracyclines regimens shoved a DFS benefit for higher doses
in pts HER2+ but not in pts HER2- (result not statistically significant)
Dhesy-Thind B Breast Cancer Res and Trt 2008
![Page 10: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/10.jpg)
BC cells with TOP2A amplification are more sensitive to anthraciclinesBC cells with TOP2A deletions are resistant to anthraciclines
(Jarvinen TAH Am J Pathol 2000)
TOP2A and Responsiveness of BC to Adjuv.CT (F.P.O’Malley JNCI/09)
438/710 premenopausal pts N+, Rand CEF vs CMF ( MA.5 trial)In pts with TOP2A alteration CEF > CMF in terms of: RFS (HR, 0.35; P= .005) and OS (HR, 0.33; P=.008)
ImplicationsThe degree of responsiveness similar to that observed in pts with HER2 amplifTumors normal forTOP2A and HER2 do not derive benefit from athracyclinesMeasurements of TOP2A alteration/HER2 amplif. have similar value in guiding
LimitationsClose but not complete concordance between TOP2A and HER2
TOP2A protein overexpression not closely correlated to TOP2A amplificationLarger number of pts will be needed to determine which measurement is mostclosely associated with responsiveness to anthracyclines regimens
![Page 11: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/11.jpg)
Predictive Power of TOP2A
Adjuvant Incidence TOP2A Predictive findingsabnormalities
BCIRG005 no TOP2A amplif.cases Improved efficacy of anthra without HER2 amplif. restricted to pts with
BCIRG 006 35% HER2 amplified HER2/TOP2A co-amplificationalso TOP2A amplified
DFS and OS better in both trastuzumab arms vs AC→D
HER2/TOP2A coamplified tumorsAC→D ~ DHCarbo or AC→DH→HHER2+tumors without amplified TOP2ADHCarbo ~ AC→DH→H
Toxicity of AnthracyclinesDC > AC (USON 9735) DC → HER2-
DHCarbo→ HER2+
![Page 12: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/12.jpg)
Predictive Power of TOP2A
Adjuvant Incidence TOP2A Predictive findings
abnormalities
BCIRG005/006 no TOP2A amplif. Improved efficacy of anthra
without HER2 amplif. restricted to pts with
35% HER2 amplified HER2/TOP2A co-amplificationalso TOP2A amplifed
NCIC MA.5 deletions 6.9% TOP2A abnormality predictor for
(N,447) amplification 11.9% benefit from CEF vs CMF (OS);
normal 81.2% more marked benefit for deletions
![Page 13: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/13.jpg)
Predictive Power of TOP2A
Adjuvant Incidence TOP2A Predictive findings
abnormalities
Di Leo (N,430) HER2 amplif. 21%; Anthra>CMF may be in ptsTOP2 amplif. 23/61 with HER2 amplf. and equally
HER2 amplif.tumors active in HER2 non amplified;
(38%) superiority of anthra may beconfined to HER2/TOP2Acoamplified subgroup
Scandinavian HER2 amplif 32.7% HER2 no predictive of 2
Breast group TOP2A coamplif 37% anthra-based CT regimens;
Trial 9401 of HER2 amplif TOP2A amplif may predict the
(N,396) efficacy of dose escalated FEC
in HER2 coamplified (HR,0.45)
![Page 14: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/14.jpg)
Predictive Power of TOP2A
Advanced Incidence TOP2A Predictive findingsabnormalities
Cardoso no TOPA2 alterations HER2 amplif did not correlate with(Int J Onc 04) without HER2 amplif response to anthracyclines;(N,59/350 screened) TOP2A amplif/overexpr correlated
to response to anthracyclines
Park 19 cases coaplificated RR to anthra higher with coamplif(EJC 2003) HER2 and TOPA2; lower without coamplification;(N,67) 12 amplif HER alone; HER2 amplif alone intermediate
RR36 cases no HER/TOPA2amplification
![Page 15: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/15.jpg)
However some studies found:
TOP2A amplification in 10 % of cases without HER2 amplification;
Deletions rather than amplifications in 50% of HER2 amplified cases;
TOP2A deletions and amplifications within individual tumors.
Bofin AM Cytopahtol 2003; Olsen KE Acta Oncol 2004;Jarvinen TA GCC 1999
Jarvinen TA Curr Cancer Drug targets 2006
NSABP B23 (B. Fisher JCO 2001)
Pts HER2+ appeared to benefit more from CMF than from AC
(HR, 1.27; P= .46)
In pts without TOP2A protein overexpression no difference in outcame
In pts with TOP2A overexpression outcame appeared better with CMF
![Page 16: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/16.jpg)
The role of TOPO2A as a predictive factors for anthracyclines activity still unclear
The data from clinical trials linking TOPO2A amplification with selectivebenefit from anthracyclines remain weak because of small sample size;
Anthracyclines have many mechanisms of action other than TOP2Ainhibition;
Expression and enzymatic activity of TOP2A increase with cellproliferation, indipendent of any gene amplification;
Technical differences in the methods of TOP2A analysis (lack ofcorrelation between gene copy number and protein expression);
Currently there is not standardized test for TOP2A
![Page 17: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/17.jpg)
Summary
Anthracyclines have been shown to be one of most effective agents in
Breast Cancer, and changing treatment requires robust evidence
Data from a single trial (USO 9735) and from retrospective subgroup
analyses are intriguing but require substantiation before….
In HER2+ pts data from BCIRG 006 trial (unpubliblished that only
reached interim analysis) should interpreted cautiously (4 published
trials support treatment with trastuzumab with anthracyclines ± taxane
backbone)
Waiting the results of DC vs DAC trial (USO 06090), trials so far support
the use of taxanes + anthracyclines in adjuvant therapy
![Page 18: HOT TOPICS IN BREAST CANCER 11 NOVEMBRE 2009 CHIETI Mediterranean School of Oncology Prof Corrado Ficorella Università degli Studi dell’Aquila.](https://reader036.fdocuments.in/reader036/viewer/2022072005/56649cdc5503460f949a73f6/html5/thumbnails/18.jpg)
Summary
Less cardiotoxic liposomal doxorubicin and schedules should beevaluated
Priority should be given to prospective trials:sequential anthracyclines/taxane schedules and/or dose denseregimens vs non-anthracyclines containing regimens
Not all pts benefit from anthracycline: genetic assays need to bereliable and validated
A prospective trial, powered for survival, to analyse predictive power ofof a TOP2A assay would help….